Satellite Symposium @ AAP: Clinical Advances and New Insights in the Management of Pediatric Atopic Dermatitis

The treatment of Atopic Dermatitis (AD) is a clinical challenge. Current treatment regimens are not curative, and patients and caregivers are frequently dissatisfied with and poorly adherent to treatment (O’Toole 2013; Snyder 2015).  The chronic nature of AD demands that clinicians be able to create flexible long-term treatment plans that evolve according to patient need. As more is understood about the disease, it has become apparent that not all forms of AD are epidemiologically and/or clinically equal (Malajian 2015). Managing this disease is crucial as it is very common and usually chronic.  This course addresses the most up-to-date protocols to treat AD and offers in-depth insights through case analysis.

Target Audience

This activity is designed for an audience of physicians, nurses, pharmacists and other healthcare professionals.

Learning Objectives

  • Identify AD based on the evaluation of clinical characteristics specific to infants, children, and adolescents.
  • Examine the efficacy and safety of current non-pharmacological and pharmacological treatments for AD patients across the age spectrum.
  • Define the rationale and mechanism of action for the use of new and emerging agents, including crisaborole, dupilumab, and oral JAK inhibitors in the management of AD.
  • Develop individualized treatment plans for pediatric patients with AD based on the efficacy and safety of current and new agents, treatment recommendations, and patient and caregiver preferences.
Course summary
Available credit: 
  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC
  • 1.50 Participation
Course opens: 
12/12/2020
Course expires: 
12/12/2021
Rating: 
0
  1. Opening remarks and pre-survey - Lawrence Schachner, MD
  2. Review of Diagnosis and Management Strategies for AD - Mercedes Gonzalez, MD
    1. Practical diagnosis of pediatric AD: different diagnosis, clinical presentation, and practical AD
      assessment tools 
    2. Review of non-pharmacologic strategies for pediatric AD including bathing and skin cleaning, use of 
      moisturizers, wet dressings and patient education. 
  1. New and Emerging Therapies for AD - Lawrence Schachner, MD
    • Conventional therapies for pediatric AD
      • Topical corticosteroids, topical calcineurin inhibitors, traditional systemic agents 
      • Efficacy and safety 
    • New and emerging agents for AD - evidence on the pediatric population
      • Crisaborole, dupilumab, topical JAK inhibitors, and IL inhibitors
      • Efficacy and safety
    • Advances in the understanding of AD pathophysiology
      •   The role of inflammation, skin barrier dysfunction, and JAK/STAT pathway
  2. Applying the evidence to practice: interactive patient cases on AD diagnosis and management - Fernanda Schmidt, MD & Mercedes Gonzalez, MD
    1. Case 1 - Mild AD
      1. Topical therapy choices and strategies for prevention 
    2. Case 2 - Severe AD
      1. Systemic therapies and disease management 
    3. Case 3 - Moderate-Severe AD (infant)
      1. Clinical diagnosis, risk factors, AD pathogenesis, AD and food allergies 
  3. Conclusions, Q&A, and post-survey

imageMercedes E. González, MD, FAAD
Medical Director, Pediatric Dermatology of Miami
Assistant Professor, University of Miami
Miller School of Medicine,
Dr. Phillip Frost Department of Dermatology and Herbert Wertheim College of Medicine
Miami, FL

Mercedes Gonzalez, MD has disclosed the following:
Consultant: Pierre Fabre, Regeneron Pharmaceuticals, Sanofi-Genzyme, Unilever, Inc., Verrica Pharmaceuticals
Contracted Research: Abbvie, Arcutis, Krystal Biotech, Novan, Pfizer, Regeneron Pharmaceuticals, Verrica Pharmaceuticals
Royalty: Wolters Klower
Speakers Bureau: Galderma, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals, Sanofi-Genzyme, Verrica Pharmaceuticals

 

image

Lawrence A. Schachner, MD
Professor,Chair Emeritus & Stiefel Laboratories Chair
Director of the Division of Pediatric Dermatology
Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery
Professor of Pediatrics
University of Miami Miller School of Medicine
Miami, FL

Lawrence A. Schachner, MD has disclosed the following:
Consultant: Biofrontera, Hoth
Contracted Research: Celgene, Pfizer
Speakers Bureau: Celgene, Pfizer, Sanofi/Genzyme, Regeneron
Stock: Top MD

 

image

Fernanda Bellodi Schmidt, MD
Assistant Professor
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine
Miami, FL

Fernanda B. Schmidt, MD has nothing to disclose.

C:\Documents and Settings\Ladams\Desktop\AKH LOGO.pngCME/CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare
 

Physicians
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDERM. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Physician Assistants 

NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Nurses

AKH, Inc., Advancing Knowledge in Healthcare is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. 

This activity is awarded 1.5 Contact Hours. 

Activity is jointly-provided by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDERM

Pharmacists 

AKH, Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.image

AKH, Inc., Advancing Knowledge in Healthcare approves this knowledge -based activity for 1.5 contact hour(s) 0.15 CEUs). UAN 0077-9999-20-024-H04-P.  Release Date: December 15, 2020

Commercial Support
This activity is supported by an educational grant from Pfizer Inc.
 

SBS FACULTY DISCLOSURES

NAME

RELATIONSHIP

COMPANY

Mercedes Gonzalez, MD

Consultant

Pierre Fabre, Regeneron Pharmaceuticals, Sanofi-Genzyme, Unilever, Inc., Verrica Pharmaceuticals

Contracted Research

Abbvie, Arcutis, Krystal Biotech, Novan, Pfizer, Regeneron Pharmaceuticals, Verrica Pharmaceuticals

Royalty

Wolters Klower

Speakers Bureau

Galderma, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals, Sanofi-Genzyme, Verrica Pharmaceuticals

Lawrence A. Schachner, MD

Consultant

Biofrontera, Hoth

Contracted Research

Celgene, Pfizer

Speakers Bureau

Celgene, Pfizer, Sanofi/Genzyme, Regeneron

 

Stock

Top MD

Fernanda B. Schmidt, MD

N/A

Nothing to disclose

PLANNER DISCLOSURES

Dorothy Caputo, MA, BSN, RN - CE Director of Accreditations

N/A

Nothing to disclose

Dorothy Duffy, PharmD

N/A

Nothing to disclose

AKH Planners and Reviewers

N/A

Nothing to disclose

 

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosure Declaration

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.

AKH Inc. Privacy Policy
Continuing Medical Education and Continuing Education

When you register for a Continuing Medical Education (CME) or a Continuing Education (CE) activity through one of our Web sites, we collect certain personally identifiable information from you such as your name, email address and mailing address. If you are a pharmacist and wish to receive CE credit, you are also required to provide your NAPB # and month and day of birth. For more information about NABP and CPE Monitor click here. In addition to personally identifiable information, we collect aggregated non-personally identifiable information about the activities undertaken by our users. We use the information that we collect through CME/CE activities in several ways:

  • We work with several accredited companies who are accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. As a joint-provider, we are required periodically to submit aggregated data about CME participants and the CME activities we certify. We also provide personally identifiable information to other accredited CME/CE providers who certify CME/CE activities posted on our Web sites, as required by the ACCME and other accrediting bodies. These reports may include personally identifiable information about you and credits issued to you, for the purpose of maintaining records that you can request from the accredited provider for up to six (6) years.
  • Commercial supporters of CME/CE activities on our Web site will receive only aggregated data about CME/CE activities that are relevant to their interests and/or the courses they support.
  • Our Editorial and Customer Support Staff will have internal access to files containing personally identifiable information, including evaluation forms and aggregated CME /CE participant information. These files can be accessed in order to respond to your questions or comments. Our staff may also use personally identifiable information, including registration information and evaluation data, in assessing educational needs and planning marketing activities.

We may use the information we collect as otherwise permitted in this Privacy Policy.

Available Credit

  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC
  • 1.50 Participation
Please login or register to take this course.

Required Hardware/software

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.